Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer. | Mol Oncol | 2026 | 41437733 | PubTator, text mining | PubMed |
| Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. | Int J Gynaecol Obstet | 2026 | 41432226 | PubTator, text mining | PubMed |
| Folate receptor alpha in platinum-resistant ovarian cancer: prevalence in a multicenter Polish cohort and review of the evidence. | Clin Transl Oncol | 2026 | 41428174 | PubTator, text mining | PubMed |
| Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery. | Bioconjug Chem | 2026 | 41412973 | PubTator, text mining | PubMed |
| Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models. | Int J Gynecol Cancer | 2026 | 41411700 | PubTator, text mining | PubMed |
| Dual pH-Responsive Calcium Phosphate Nanoparticles Conjugated with Folate by CuAAC Click Chemistry for Targeted Gemcitabine Delivery to Cancer Cells. | ACS Appl Bio Mater | 2026 | 41400640 | PubTator, text mining | PubMed |
| Evaluation of Pafolacianine (Cytalux®) for Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma: A Negative Study with Important Clinical Implications. | Mol Imaging Biol | 2026 | 41379363 | PubTator, text mining | PubMed |
| Site-Specific Capsid Modification Enables FRα-Directed Retargeting of AAV for Precision Gene Delivery. | Mol Pharm | 2026 | 41335022 | PubTator, text mining | PubMed |
| A high-throughput approach to optimize and understand nanoparticle protein degraders. | Nanoscale Adv | 2026 | 41334459 | PubTator, text mining | PubMed |
| [18F]AzaFol PET captures folic acid dynamics at folate receptors in the brain. | J Cereb Blood Flow Metab | 2026 | 41320870 | PubTator, text mining | PubMed |
| An integrated microfluidic system equipped with a shear force control device for optimized selection of high-affinity, high-specificity aptamers targeting folate receptor alpha. | Anal Chim Acta | 2026 | 41285542 | PubTator, text mining | PubMed |
| Signaling and Mechanistic Insights into Folate Binding Protein-Induced Cytotoxicity in KB Cancer Cells. | Mol Pharm | 2026 | 41284853 | PubTator, text mining | PubMed |
| Exploring novel therapeutic targets in vulvar squamous cell carcinoma. | Gynecol Oncol | 2026 | 41275789 | PubTator, text mining | PubMed |
| Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma. | Int J Gynecol Pathol | 2026 | 41217393 | PubTator, text mining | PubMed |
| A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer. | Clin Cancer Res | 2026 | 41213103 | PubTator, text mining | PubMed |
| BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer. | Mol Ther | 2026 | 41029902 | PubTator, text mining | PubMed |
| Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review. | Clin Transl Oncol | 2026 | 40924376 | PubTator, text mining | PubMed |
| Folate receptor alpha (FRα/FOLR1) and HER2 immunohistochemical staining in high-grade endometrial carcinoma with aberrant p53 expression. | Histopathology | 2026 | 40769949 | PubTator, text mining | PubMed |
| Antibody-drug Conjugate Biomarker Expression in Gestational Trophoblastic Disease: Folate Receptor Alpha, Nectin-4, Trop-2, and Tissue Factor. | Int J Gynecol Pathol | 2026 | 40644332 | PubTator, text mining | PubMed |
| FOLR1 Regulates the Malignant Progression of Glioblastoma through the SRC/ERK1/2 Axis. | Comb Chem High Throughput Screen | 2026 | 39838671 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=9